INCRNasdaqPharmaceutical PreparationsFiscal year ends December 31

Intercure Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026

$4.46−0.11 (-2.41%)

Close on Oct 19, 2026

Intercure Ltd. cash flow statement

AnnualQuarterlyTTM

Millions of ILS, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Depreciation & Amortization	17	15	13	12	7.39	3.25	0.83
Stock-Based Compensation	2.43	2.28	2.59	8.91	6.45	10	68
Deferred Income Taxes	-7.32	-15	2.25	0.09	11	-2.27	-0.67
Change in Inventory	11	-13	35	-75	-15	-14	3.03
Operating Cash Flow	17	-67	-54	51	30	7.90	-12
Capital Expenditures	-3.55	-4.38	-2.62	-20	-14	-21	-28
Acquisitions	–	–	–	–	-19	0.39	0.39
Sale of Property, Plant & Equipment	–	–	0.03	–	–	–	–
Investing Cash Flow	-1.99	18	4.77	-142	-65	-23	-26
Debt Issued	10	188	63	263	75	0.67	–
Debt Repaid	-45	-175	-120	-121	-3.42	–	-0.17
Financing Cash Flow	-47	26	-83	120	198	25	63
Foreign Exchange Rate Adjustments	-0.04	-0.04	0.30	7.16	-4.54	0.22	-1.66
Free Cash Flow	13	-71	-56	32	16	-13	-40
Income Taxes Paid	-0.31	13	7.61	7.97	12	–	0.05

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: 12.3%
Operating margin: -10.1%
Net margin: -13.2%
Return on equity, FY2025: -9.0%

Financial strength

Current ratio: –
Debt to equity: 0.49
Debt to assets: 28.3%
Cash to current liabilities: 21.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.